Montreal-based Medical Device Company EMcision Ranks No. 14 on the 2013 PROFIT HOT 50

Share Article

PROFIT Magazine today ranked EMcision International Inc. No. 14 on its 14th annual PROFIT HOT 50, the definitive ranking of Canada’s Top New Growth Companies.

News Image
This achievement reflects the strength of our devices, the dedication of our team and the momentum we’ve been steadily building. We will continue to develop innovative products to help patients.

PROFIT Magazine today ranked EMcision International Inc. No. 14 on its 14th annual PROFIT HOT 50, the definitive ranking of Canada’s Top New Growth Companies. Published in the October issue of PROFIT Magazine and online at PROFITguide.com, the PROFIT HOT 50 ranks young firms by two-year revenue growth.

“We are delighted and proud to be on the PROFIT HOT 50 ranking,” says Cherif Habib, EMcision’s CEO. “This achievement reflects the strength of our devices, the dedication of our team and the momentum we’ve been steadily building. We will continue to develop innovative products to help patients.”

EMcision recently announced the sale of the first units of its new device, the Habib™ RF DUO 13 catheter – a long, thin tube that sends electric pulses to destroy malignant cells that has immense potential to help abdominal cancer patients. The device is currently approved for sale in Europe and China.

“This year’s PROFIT HOT 50 companies embody the entrepreneurial spirit,” says Ian Portsmouth, Publisher and Editor-in-Chief of PROFIT Magazine. “They have grown exceptionally fast in a challenging economy, thanks to the ingenuity and determination of the entrepreneurs behind them.”

About EMcision
EMcision was founded by internationally renowned surgeon and inventor of medical devices, Professor Nagy Habib, to develop proprietary medical devices based on proven RF technology for the surgical community. Devices for endoscopists and interventional radiologists soon followed. In 2002, EMcision developed the Habib™ 4X for the treatment of liver cancer, which has the reputation of being the #1 hepatic resection device in the U.S. The company combines scientific, commercial and management skills, brought together in a working partnership to develop and commercialize medical devices that are clinically relevant, cost-effective and enhance the quality of life of cancer patients. EMcision's R&D, engineering and commercialization operations are based in Montreal, and clinical activities are based at the Imperial College London (U.K.) and Hammersmith Hospital.

About PROFIT Magazine
PROFIT: Your Guide to Business Success is Canada’s preeminent publication dedicated to the management issues and opportunities facing small and mid-sized businesses. For 31 years, Canadian entrepreneurs and senior managers across a vast array of economic sectors have remained loyal to PROFIT because it’s a timely and reliable source of actionable information that helps them achieve business success and get the recognition they deserve for generating positive economic and social change. Visit PROFIT online at http://www.PROFITguide.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cherif Habib
Visit website